Should Patients Receive Secondary Prevention Medications For Free After A Myocardial Infarction? An Economic Analysis
作者： Niteesh K. Choudhry , Jerry Avorn , Elliott M. Antman , Sebastian Schneeweiss , William H. Shrank
关键词:
摘要: Taken in combination, aspirin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and statins (combination pharmacotherapy) greatly reduce cardiac events. These therapies are underused, even among patients with drug insurance. Out-of-pocket spending is a key barrier to adherence. We estimated the impact of providing combination pharmacotherapy without cost sharing (“full coverage”) insured after myocardial infarction (MI). Under base-case assumptions, compared standard coverage, three years full coverage will mortality reinfarction rates save $5,974 per patient. Our analysis suggests that covering therapy for such both lives money.
harvard.edu
sci-hub.se 参考文章(13)
M E Chernew, A M Fendrick, D G Smith, S N Shah, A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. The American Journal of Managed Care. ,vol. 7, pp. 861- 867 ,(2001)
Dana P. Goldman, Geoffrey F. Joyce, Pinar Karaca-Mandic, Varying pharmacy benefits with clinical status: The case of cholesterol-lowering therapy The American Journal of Managed Care. ,vol. 12, pp. 21- 28 ,(2006)
Dana P Goldman, Geoffrey F Joyce, Jose J Escarce, Jennifer E Pace, Matthew D Solomon, Marianne Laouri, Pamela B Landsman, Steven M Teutsch, Pharmacy Benefits and the Use of Drugs by the Chronically Ill JAMA. ,vol. 291, pp. 2344- 2350 ,(2004) , 10.1001/JAMA.291.19.2344
Allison B. Rosen, Mary Beth Hamel, Milton C. Weinstein, David M. Cutler, A. Mark Fendrick, Sandeep Vijan, Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Annals of Internal Medicine. ,vol. 143, pp. 89- 99 ,(2005) , 10.7326/0003-4819-143-2-200507190-00007
Milton C. Weinstein, Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. ,vol. 276, pp. 1253- 1258 ,(1996) , 10.1001/JAMA.1996.03540150055031
Winnie W. Nelson, David H. Smith, Susan E. Andrade, Stephen B. Soumerai, Douglas W. Roblin, Richard Platt, Michael J. Goodman, John Hsu, Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Medical Care. ,vol. 43, pp. 951- 959 ,(2005) , 10.1097/01.MLR.0000178216.23514.B7
Marcus D Flather, Salim Yusuf, Lars Køber, Marc Pfeffer, Alistair Hall, Gordon Murray, Christian Torp-Pedersen, Stephen Ball, Janice Pogue, Lemuel Moyé, Eugene Braunwald, Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients The Lancet. ,vol. 355, pp. 1575- 1581 ,(2000) , 10.1016/S0140-6736(00)02212-1
John Kjekshus, Terje R. Pedersen, Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin survival study (4S) American Journal of Cardiology. ,vol. 76, pp. 64- ,(1995) , 10.1016/S0002-9149(99)80473-1
Lawrence Liao, James G Jollis, Kevin J Anstrom, David J Whellan, Dalane W Kitzman, Gerard P Aurigemma, Daniel B Mark, Kevin A Schulman, John S Gottdiener, Costs for heart failure with normal vs reduced ejection fraction. JAMA Internal Medicine. ,vol. 166, pp. 112- 118 ,(2006) , 10.1001/ARCHINTE.166.1.112
William H. Shrank, Steven M. Asch, John Adams, Claude Setodji, Eve A. Kerr, Joan Keesey, Shaista Malik, Elizabeth A. McGlynn, The quality of pharmacologic care for adults in the United States. Medical Care. ,vol. 44, pp. 936- 945 ,(2006) , 10.1097/01.MLR.0000223460.60033.79